PMC:7195088 / 27959-28228 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T140","span":{"begin":101,"end":109},"obj":"Disease"},{"id":"T141","span":{"begin":225,"end":233},"obj":"Disease"},{"id":"T142","span":{"begin":236,"end":245},"obj":"Disease"}],"attributes":[{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A142","pred":"mondo_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T151","span":{"begin":195,"end":196},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T369","span":{"begin":36,"end":55},"obj":"Chemical"},{"id":"T370","span":{"begin":36,"end":45},"obj":"Chemical"},{"id":"T371","span":{"begin":46,"end":55},"obj":"Chemical"}],"attributes":[{"id":"A369","pred":"chebi_id","subj":"T369","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A370","pred":"chebi_id","subj":"T370","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A371","pred":"chebi_id","subj":"T371","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T211","span":{"begin":111,"end":162},"obj":"Sentence"},{"id":"T212","span":{"begin":163,"end":180},"obj":"Sentence"},{"id":"T213","span":{"begin":181,"end":269},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. Double-blind RCT (NCT04328285, not yet recruiting). Primary endpoint: Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months)."}